Every stage of biopharma drug development depends on what happens in the laboratory. Consequently, any one of these stages—which include target identification, lead optimization, candidate ...

Drug development is a long and costly process. On the other hand, while AI platforms may rapidly identify compounds that work on cells in a Petri dish or in animal models, the success of these ...

Roche RHHBY announced that it will advance pipeline candidate prasinezumab into phase III development for early-stage Parkinson’s disease. Roche has a licensing agreement with Prothena PRTA for ...

The current drug development process operates like an assembly line, relying on a checkbox approach with extensive testing at each step of the process.While AI may be able to reduce the time and cost ...

Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced the appointments of multiple se ...

In this continuation of my last article, we will explore these challenges, the opportunities they present and the future outlook of AI-driven drug development.

The decision to advance prasinezumab to late-stage development was based on data from the phase IIb PADOVA study and ongoing open-label extensions (OLEs) of PADOVA and phase II PASADENA studies.